{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T14:06:37Z","timestamp":1779372397087,"version":"3.53.1"},"posted":{"date-parts":[[2026,5,19]]},"group-title":"Radiology and Imaging","reference-count":37,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,5,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>\n                    Amyloid-\n                    <jats:bold>\n                      <jats:italic>\u03b2<\/jats:italic>\n                    <\/jats:bold>\n                    PET provides critical biomarker data for Alzheimer\u2019s disease diagnosis and anti-amyloid therapy evaluation, yet low spatial resolution and partial volume effects result in decreased interpretability, particularly in cases with low or borderline cortical amyloid burden. While quantitative metrics (SUVr, Centiloid) aid in interpretation of amyloid burden, disagreement between visual reads and quantitative burden does occur, further blurring the line between positive or negative scans. We evaluated whether a vendor-neutral MR-guided PET denoising and resolution enhancement method (MRG) that uses Bowsher regularization improves image interpretability and reader performance while preserving established quantitative biomarkers across multiple amyloid tracers, leading to increased concordance among visual reads and quantitative metrics.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>\n                    Standard (STN) and MRG PET images were compared for four tracers ([\n                    <jats:sup>\n                      <jats:bold>18<\/jats:bold>\n                    <\/jats:sup>\n                    F]AV-45 ([\n                    <jats:sup>\n                      <jats:bold>18<\/jats:bold>\n                    <\/jats:sup>\n                    F]florbetapir, FBP), [\n                    <jats:sup>\n                      <jats:bold>18<\/jats:bold>\n                    <\/jats:sup>\n                    F]florbetaben (FBB), [\n                    <jats:sup>\n                      <jats:bold>18<\/jats:bold>\n                    <\/jats:sup>\n                    F]flutemetamol (FMM), and [\n                    <jats:sup>\n                      <jats:bold>11<\/jats:bold>\n                    <\/jats:sup>\n                    C]Pittsburgh compound-B (PiB)) collectively from 24 MRI and 33 PET scanners. Quantitative equivalence was assessed by comparing Standardized Uptake Value ratio (SUVr) and Centiloid scores. In three of the four tracers (FBP, FBB, FMM), visual-quantitative concordance (AUC) and reader performance were evaluated in a blinded multi-reader study by four highly experienced brain PET readers who assessed image quality, artifact severity, reader confidence, and binary amyloid positivity.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    Across all tracers, MRG preserved quantitative SUVr and Centiloid metrics relative to STN (\n                    <jats:bold>\n                      <jats:italic>R<\/jats:italic>\n                    <\/jats:bold>\n                    <jats:sup>\n                      <jats:bold>2<\/jats:bold>\n                    <\/jats:sup>\n                    &gt;\n                    <jats:bold>0.90<\/jats:bold>\n                    for all tracers) without introducing bias to the SUVr metric. Concordance between visual reads and quantitative burden measures significantly improved with MRG. In the multi-reader study, MRG resulted in significantly higher image quality, lower artifact burden, and greater reader confidence compared to STN (\n                    <jats:bold>\n                      <jats:italic>p<\/jats:italic>\n                    <\/jats:bold>\n                    &lt;\n                    <jats:bold>0.0001<\/jats:bold>\n                    ). Reader accuracy increased from 0.89 to 0.94, and the false-negative rate decreased from 0.08 to 0.04. Crucially, improvements in reader confidence, accuracy, and the reduction in false negative reads were most pronounced in cases with low amyloid burden near the threshold of visual positivity.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>MRG denoising and resolution enhancement improved perceived image quality, reader confidence, and accuracy for amyloid PET while preserving standard quantitative behavior across tracers. By improving cortical definition in visually challenging low-burden cases without disrupting established SUVr\/Centiloid behavior, MRG may reduce visual-quantitative discordance and support more confident amyloid PET interpretation near the threshold of positivity.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.05.14.26353149","type":"posted-content","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:35:13Z","timestamp":1779212113000},"source":"Crossref","is-referenced-by-count":0,"title":["MR-Guided PET Denoising and Resolution Enhancement Improves Visual Interpretation and Preserves Quantitative Behavior Across Amyloid Tracers"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1291-7492","authenticated-orcid":false,"given":"Caroline","family":"Szujewski","sequence":"first","affiliation":[{"name":"Microstructure Imaging, Inc., 370 Jay St FL7, Brooklyn, 11201, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0232-1636","authenticated-orcid":false,"given":"Timothy M.","family":"Shepherd","sequence":"additional","affiliation":[{"name":"Department of Radiology, NYU Langone Health, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1044-0136","authenticated-orcid":false,"given":"Munir","family":"Ghesani","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mount Sinai Health System, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-8971","authenticated-orcid":false,"given":"Maria","family":"Ponisio","sequence":"additional","affiliation":[{"name":"Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Lavely","sequence":"additional","affiliation":[{"name":"Northside Radiology Associates, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2251-3195","authenticated-orcid":false,"given":"Georg","family":"Schramm","sequence":"additional","affiliation":[{"name":"Department of Imaging and Pathology, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9169-7530","authenticated-orcid":false,"given":"Ariane","family":"Bollack","sequence":"additional","affiliation":[{"name":"GE HealthCare, Chalfont St Giles, HP8 4SP, UK"},{"name":"Department of Medical Physics and Biomedical Engineering, University College London, London, WC1E 6BT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5077-3341","authenticated-orcid":false,"given":"Benjamin","family":"Aron","sequence":"additional","affiliation":[{"name":"Microstructure Imaging, Inc., 370 Jay St FL7, Brooklyn, 11201, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8336-7486","authenticated-orcid":false,"given":"Gregory","family":"Lemberskiy","sequence":"additional","affiliation":[{"name":"Microstructure Imaging, Inc., 370 Jay St FL7, Brooklyn, 11201, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026052106151223000_2026.05.14.26353149v1.1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70235"},{"key":"2026052106151223000_2026.05.14.26353149v1.2","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup","volume":"20","year":"2024","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2026052106151223000_2026.05.14.26353149v1.3","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004643"},{"key":"2026052106151223000_2026.05.14.26353149v1.4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease","volume":"9","year":"2022","journal-title":"The Journal of Prevention of Alzheimer\u2019s Disease"},{"key":"2026052106151223000_2026.05.14.26353149v1.5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2100708"},{"key":"2026052106151223000_2026.05.14.26353149v1.6","unstructured":"Ivanidze, J. et al. PET-guided Assessment of Amyloid Clearance and Outcomes in a Real-World Cohort of Patients with Alzheimer Disease undergoing Anti-Amyloid Therapy."},{"key":"2026052106151223000_2026.05.14.26353149v1.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263195"},{"key":"2026052106151223000_2026.05.14.26353149v1.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268339"},{"key":"2026052106151223000_2026.05.14.26353149v1.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268756"},{"key":"2026052106151223000_2026.05.14.26353149v1.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268119"},{"key":"2026052106151223000_2026.05.14.26353149v1.11","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000001693"},{"key":"2026052106151223000_2026.05.14.26353149v1.12","doi-asserted-by":"crossref","first-page":"578753","DOI":"10.3389\/fneur.2020.578753","article-title":"Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer\u2019s Disease: A Multicenter Study","volume":"11","year":"2021","journal-title":"Front. Neurol"},{"key":"2026052106151223000_2026.05.14.26353149v1.13","doi-asserted-by":"crossref","first-page":"103765","DOI":"10.1016\/j.nicl.2025.103765","article-title":"A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research","volume":"46","year":"2025","journal-title":"NeuroImage: Clinical"},{"key":"2026052106151223000_2026.05.14.26353149v1.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05784-y"},{"key":"2026052106151223000_2026.05.14.26353149v1.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.106.035774"},{"key":"2026052106151223000_2026.05.14.26353149v1.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.238477"},{"key":"2026052106151223000_2026.05.14.26353149v1.17","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X231152001"},{"key":"2026052106151223000_2026.05.14.26353149v1.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266463"},{"key":"2026052106151223000_2026.05.14.26353149v1.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265766"},{"key":"2026052106151223000_2026.05.14.26353149v1.20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s12194-025-00882-6","article-title":"Age-related sensitivity deterioration evaluation of positron emission tomog-raphy utilizing cross-calibration factor measurement data","volume":"18","year":"2025","journal-title":"Radiol Phys Technol"},{"key":"2026052106151223000_2026.05.14.26353149v1.21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s12149-010-0381-y","article-title":"Long-term performance evaluation of positron emission tomography: analysis and proposal of a maintenance protocol for long-term utilization","volume":"24","year":"2010","journal-title":"Ann Nucl Med"},{"key":"2026052106151223000_2026.05.14.26353149v1.22","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-024-01977-7"},{"key":"2026052106151223000_2026.05.14.26353149v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2014.11.058"},{"key":"2026052106151223000_2026.05.14.26353149v1.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267767"},{"key":"2026052106151223000_2026.05.14.26353149v1.25","first-page":"1","article-title":"The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET","volume":"11","year":"2015","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2026052106151223000_2026.05.14.26353149v1.26","doi-asserted-by":"publisher","DOI":"10.1109\/TMI.2017.2767940"},{"key":"2026052106151223000_2026.05.14.26353149v1.27","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1109\/NSSMIC.2004.1462760","volume-title":"In IEEE Symposium Conference Record Nuclear Science 2004","volume":"4","year":"2004"},{"key":"2026052106151223000_2026.05.14.26353149v1.28","doi-asserted-by":"publisher","DOI":"10.1101\/2025.01.04.25319996"},{"key":"2026052106151223000_2026.05.14.26353149v1.29","doi-asserted-by":"publisher","DOI":"10.1002\/mp.13812"},{"key":"2026052106151223000_2026.05.14.26353149v1.30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/alzrt276","article-title":"Imaging as a biomarker in drug discovery for Alzheimer\u2019s disease: is MRI a suitable technology?","volume":"6","year":"2014","journal-title":"Alz Res Therapy"},{"key":"2026052106151223000_2026.05.14.26353149v1.31","doi-asserted-by":"crossref","first-page":"100343","DOI":"10.1016\/j.ynirp.2026.100343","article-title":"Comparability of Centiloid values from [18F]flutemetamol scans using seven commercial and research software","volume":"6","year":"2026","journal-title":"NeuroImage: Reports"},{"key":"2026052106151223000_2026.05.14.26353149v1.32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13550-023-00994-3","article-title":"Software compatibility analysis for quantitative measures of [18F]flutemetamol amyloid PET burden in mild cognitive impairment","volume":"13","year":"2023","journal-title":"EJNMMI Res"},{"key":"2026052106151223000_2026.05.14.26353149v1.33","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3749-6"},{"key":"2026052106151223000_2026.05.14.26353149v1.34","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-018-0456-7"},{"key":"2026052106151223000_2026.05.14.26353149v1.35","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","article-title":"Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale","volume":"14","year":"2018","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2026052106151223000_2026.05.14.26353149v1.36","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.153494"},{"key":"2026052106151223000_2026.05.14.26353149v1.37","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270607"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.05.14.26353149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T13:15:20Z","timestamp":1779369320000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.05.14.26353149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":37,"URL":"https:\/\/doi.org\/10.64898\/2026.05.14.26353149","relation":{},"subject":[],"published":{"date-parts":[[2026,5,19]]},"subtype":"preprint"}}